1. Home
  2. HSCS vs INDP Comparison

HSCS vs INDP Comparison

Compare HSCS & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heart Test Laboratories Inc.

HSCS

Heart Test Laboratories Inc.

HOLD

Current Price

$2.63

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.65

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSCS
INDP
Founded
2007
2000
Country
United States
United States
Employees
12
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HSCS
INDP
Price
$2.63
$2.65
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
4.4M
410.7K
Earning Date
03-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.63
$0.92
52 Week High
$4.39
$12.77

Technical Indicators

Market Signals
Indicator
HSCS
INDP
Relative Strength Index (RSI) 57.44 45.81
Support Level $2.61 $2.43
Resistance Level $3.18 $3.11
Average True Range (ATR) 0.41 0.36
MACD 0.01 -0.15
Stochastic Oscillator 48.77 12.10

Price Performance

Historical Comparison
HSCS
INDP

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: